Search

Your search keyword '"Mansi, Laura"' showing total 164 results
Start Over Author "Mansi, Laura"
164 results on '"Mansi, Laura"'

1. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

2. Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Author

Buisseret, Laurence, Loirat, Delphine, Aftimos, Philippe, Maurer, Christian, Punie, Kevin, Debien, Véronique, Kristanto, Paulus, Eiger, Daniel, Goncalves, Anthony, Ghiringhelli, François, Taylor, Donatienne, Clatot, Florent, Van den Mooter, Tom, Ferrero, Jean-Marc, Bonnefoi, Hervé, Canon, Jean-Luc, Duhoux, Francois P., Mansi, Laura, Poncin, Renaud, Barthélémy, Philippe, Isambert, Nicolas, Denis, Zoë, Catteau, Xavier, Salgado, Roberto, Agostinetto, Elisa, de Azambuja, Evandro, Rothé, Françoise, Craciun, Ligia, Venet, David, Romano, Emanuela, Stagg, John, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Ignatiadis, Michail, and Piccart-Gebhart, Martine

Published
2023
Full Text
View/download PDF

3. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Author

Buisseret, Laurence, Loirat, Delphine, Aftimos, Philippe, Maurer, Christian, Punie, Kevin, Debien, Véronique, Kristanto, Paulus, Eiger, Daniel, Goncalves, Anthony, Ghiringhelli, François, Taylor, Donatienne, Clatot, Florent, Van den Mooter, Tom, Ferrero, Jean-Marc, Bonnefoi, Hervé, Canon, Jean-Luc, Duhoux, Francois P., Mansi, Laura, Poncin, Renaud, Barthélémy, Philippe, Isambert, Nicolas, Denis, Zoë, Catteau, Xavier, Salgado, Roberto, Agostinetto, Elisa, de Azambuja, Evandro, Rothé, Françoise, Craciun, Ligia, Venet, David, Romano, Emanuela, Stagg, John, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Ignatiadis, Michail, and Piccart-Gebhart, Martine

Published
2023
Full Text
View/download PDF

4. A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study

Author

Drozd, Chloé, Curtit, Elsa, Jacquinot, Quentin, Marquine, Charlène, Mansi, Laura, Chaigneau, Loïc, Dobi, Erion, Viot, Julien, Meynard, Guillaume, Paillard, Marie-Justine, Goujon, Morgan, Roux, Pauline, Vernerey, Dewi, Gillet, Valérie, Bourdin, Hubert, Galli, Silvio, Meneveau, Nathalie, and Mougin, Fabienne

Published
2023
Full Text
View/download PDF

5. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients

Author

Gauduchon, Thibault, Kfoury, Maria, Lorusso, Domenica, Floquet, Anne, Ventriglia, Jole, Salaun, Hélène, Moubarak, Malak, Rivoirard, Romain, Polastro, Laura, Favier, Laure, You, Benoit, Berton, Dominique, de la Motte Rouge, Thibault, Mansi, Laura, Abdeddaim, Cyril, Prulhiere, Karine, Lancry Lecomte, Laurence, Provansal, Magali, Dalban, Cécile, and Ray-Coquard, Isabelle

Published
2023
Full Text
View/download PDF

8. TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Author

Kabirian, Rayan, Tredan, Olivier, Marmé, Frederik, Paoletti, Xavier, Eberst, Lauriane, Lebreton, Coriolan, De La Motte Rouge, Thibault, Sabatier, Renaud, Angelergues, Antoine, Fabbro, Michel, Van Gorp, Toon, Mansi, Laura, Gladieff, Laurence, Kaczmarek, Emilie, Alexandre, Jérôme, Grellety, Thomas, Favier, Laure, Welz, Julia, Frenel, Jean-Sébastien, and Leary, Alexandra

Abstract

Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy. Clinical Trial Registration:NCT04713514 (ClinicalTrials.gov) Tweetable Abstract Ongoing Phase II study randomizing vaccine OSE2101 +/- Pembrolizumab vs supportive care as maintenance in platinum-sensitive recurrent ovarian cancer. Plain Language Summary Phase II study evaluating vaccine OSE2101 +/- Pembrolizumab vs supportive care as maintenance in patients with recurrent platinum-sensitive ovarian cancer. Ovarian cancer often becomes a long-term condition that needs ongoing treatment. After chemotherapy, women usually receive additional treatments to keep the cancer under control. There are only two approved treatments for this: bevacizumab administered every 3 weeks, and poly ADP-ribose polymerase inhibitors (PARP) inhibitors, which are pills that women can take if their cancer responds to platinum-based chemotherapy. However, if women have already been treated with both bevacizumab and a PARP inhibitor, there are no approved options left to maintain control of the cancer after chemotherapy. A new potential treatment, called OSE2101, is being studied: it is a vaccine designed to activate the body's immune cells to fight against cancer. The TEDOVA study is looking at how well this vaccine works in women with ovarian cancer who have already been treated with both bevacizumab and a PARP inhibitor and whose cancer is responding to platinum-based chemotherapy again. Participants are randomly assigned to one of three groups after their chemotherapy: standard supportive care, OSE2101 vaccine alone and the combination of OSE2101 vaccine with pembrolizumab. The goal of the TEDOVA study is to see if the combination of the OSE2101 vaccine and pembrolizumab can better control the cancer and to make sure the treatments are safe. The study is being run by ARCAGY-GINECO and is currently recruiting patients in France, Germany and Belgium. The study will continue to accept new patients until the end of 2024, and it is registered on ClinicalTrial.gov under the number NCT04713514. Article highlights Advanced epithelial ovarian cancer Most patients diagnosed with ovarian cancer (OC) have no evidence of disease after standard treatment with debulking surgery and platinum-based chemotherapy. Long-term survival depends on the recurrence of the disease, the delay between the last platinum-based chemotherapy defining the platinum-sensibility which is a major prognostic factor. Study rationale Women with platinum-sensible relapse (more than 6 months after the last platinum received) will be managed as patients with a chronic disease requiring iterative lines of platinum-based chemotherapy. After several cycles of treatment, chemotherapy is usually stopped and one of the major priorities is to extend platinum-free interval proposing maintenance strategies, as targeted therapy bevacizumab or poly ADP-ribose polymerase inhibitors (PARPi). When those lines of therapy have been received during previously, they cannot be reuse. That is the reason of developing new therapies and associations as maintenance therapy. TEDOVA study TEDOVA is a Phase II, randomized, open-label, multicenter study assessing the efficacy of vaccine OSE2101 + anti PD-1 pembrolizumab as maintenance therapy in women with platinum-sensible relapse of OC. We included women with HLA-A2 phenotype (~45% of the general population) with platinum sensitive OC regardless of the number of prior lines of platinum-based chemotherapy. Patients must have been previously treated with bevacizumab and a PARPi, or have a contra-indication. End points The primary end point is to evaluate the progression free survival of maintenance OSE2101 alone or in combination with PD1 inhibitor. The secondary end points are to compare the best overall response rate for patients with measurable disease at randomization, the safety and tolerability, the time to subsequent first and second treatments and the overall survival. Key eligibility Eligible patients were aged ≥18 years of age with histologically proven non-mucinous epithelial OC, positive HLA-A2 phenotype, and platinum sensitive OC regardless of the number of prior lines of platinum-based chemotherapy. Patients must have been previously treated with bevacizumab and a PARPi, or have a contraindication. Study procedures A total of 180 patients with an HLA-A2 positive phenotype will be randomized into three study arms in a 1:1:2 ratio: Arm A (n = 45) will receive observation/best supportive care, Arm B (n = 45) will receive OSE2101 and Arm C (n = 90) will receive OSE2101 plus pembrolizumab. Patients will be followed until disease progression, intolerance, withdrawal of consent, or for up to 2 years. Statistics One-sided log-rank tests will be conducted in a predefined sequence: H1: Compare Arm C (OSE2101 + pembrolizumab) with Arm A (best supportive care). If H1 shows a statistically significant difference, then proceed to: H2: Compare Arm C (OSE2101 + pembrolizumab) with Arm B (OSE2101). If both H1 and H2 show statistically significant differences, then proceed to: H3: Compare Arm B (OSE2101) with Arm A (best supportive care). A total of 121 events (progressions or deaths) is required to perform the first test of H1. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. To what extent do age, stage and treatment influence survival after invasive cervical cancer: a French population-based study

Author

Compaoré, Zoéwendtalé Cyrille, Monnet, Elisabeth, Gérazime, Aurélie, Molinié, Florence, Guizard, Anne-Valérie, Delafosse, Patricia, Dabakuyo-Yonli, Tienhan Sandrine, Coureau, Gaëlle, Hammas, Karima, Plouvier, Sandrine, Bara, Simona, Défossez, Gautier, Lapôtre-Ledoux, Bénédicte, Daubisse-Marliac, Laetitia, d’Almeida, Tania, Launoy, Guy, Mansi, Laura, Trétarre, Brigitte, and Woronoff, Anne-Sophie

Published
2022
Full Text
View/download PDF

11. Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice

Author

Mouillet, Guillaume, Falcoz, Antoine, Fritzsch, Joëlle, Almotlak, Hamadi, Jacoulet, Pascale, Pivot, Xavier, Villanueva, Cristian, Mansi, Laura, Kim, Stefano, Curtit, Elsa, Meneveau, Nathalie, Adotevi, Olivier, Jary, Marine, Eberst, Guillaume, Vienot, Angelique, Calcagno, Fabien, Pozet, Astrid, Djoumakh, Oumelkheir, Borg, Christophe, Westeel, Virginie, Anota, Amélie, and Paget-Bailly, Sophie

Published
2021
Full Text
View/download PDF

12. Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)

Author

Tougeron, David, Hentzien, Maxime, Seitz-Polski, Barbara, Bani-Sadr, Firouze, Bourhis, Jean, Ducreux, Michel, Gaujoux, Sébastien, Gorphe, Philippe, Guiu, Boris, Hoang-Xuan, Khê, Huguet, Florence, Lecomte, Thierry, Lièvre, Astrid, Louvet, Christophe, Maggiori, Léon, Mansi, Laura, Mariani, Pascale, Michel, Pierre, Servettaz, Amélie, Thariat, Juliette, Westeel, Virgine, Aparicio, Thomas, Blay, Jean-Yves, and Bouché, Olivier

Published
2021
Full Text
View/download PDF

14. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Moulin, Solenne, Leleu, Olivier, Leparree, Sylvie, Goasdoue, Henri, Piprot, Christine, Tourneur, Gerald, Bayart, Vincent, Lignier, Delphine, Lachaier, Emma, Khamari, Marwa, Coutte, Alexandre, Siembida, Nicolas, Houessinon, Aline, Regimbeau, Jean Marc, Chauffert, Bruno, Moreira, Aurélie, Hautefeuille, Vincent, Hee, Christine, Boone, Mathieu, Bihan, Céline, Chive, Emilie, Poulet-Potriquier, Stéphane, Fahem, Rachida, Luet, Dominique, Roquin, Guillaume, Vitellius, Carole, Cornet-Trichereau, Nathanaëlle, Caroli-Bosc, François-Xavier, Thirot-Bidault, Anne, Ropert, Stanislas, Gachet - Masson, Julie, Dehais, Mélanie, L'helgoualc'h, Gwen-Ael, Ali-Mahamadou, Ibrahim, Talfi, Safia, Belmont, Laure, Kilendo, Dieudonné, Benrezzak, Nasro, Dubief, Emeline, Conroy, Guillaume, Delique, Laurence, Basso, Maud, Pons, Isabelle, Salignon, Karine, Villing, Anne-Laure, Mougenot, Emmanuelle, Porebski, Cassandra, Guiatni, Asma, Cloarec, Nicolas, Mineur, Laurent, Bouchaud, Marie, David, Céleste, Peytier, Annie, Greletty, Thomas, Audemar, Franck, Vignes, Emanuelle, Minne, Floriane, Goldzak, Guillaume, Huysman, Fabienne, Hocine, Fayçal, Lakkis, Zaher, Mansi, Laura, Meynard, Guillaume, Almotlak, Hamadi, Klajer, Elodie, Sun, Xu-Shan, Wasselin, Julie, Catala, Pascale, Mazuy, Claire, Vandamme, Hélène, Prevost, Jean-Briac, Fadin, Aurélie, Basson, Laurent, Huguet, Jean-Baptiste, Dos Santos, Emmanuelle, Jany, Bérangère, Saad, Alain, Goutorbe, Frédéric, Oziol, Eric, Ramdani, Mohamed, Kadiri, Ouafae, Garbay, Delphine, Huet, Clotilde, Giroux Leprieur, Etienne, Teng, Wen, Monvoisin, Justine, Arnaud Coffin, Patrick, Roux, Sylvie, Orfeuvre, Hubert, Chagros, Mélanie, Pillon, Didier, Rassoul, Agathe, Poureau, Pierre Guillaume, Novello, Cécile, Ducray, François, Trouba, Cécile, Bastit, Vianney, Babin, Emmanuel, Thariat, Juliette, Leon, Vincent, Courtecuisse, Anne-Catherine, Vambre, Julie, Tack, Vincent, Desauw, Christophe, Meniai, Fatima, Peres, Christina, Esparcieux, Aurélie, Perrier, Hervé, Doux, Nathalie, Kaphan, Régis, Roques, Bertrand, Rebischung, Christine, Mille, Dominique, Fernandes, Gaëlle, Abdelli, Naceur, Jousset, Natacha, Combe, Pierre, Jonveaux, Eric, Dumont, Patrick, Kanaan, Marc, Berthelot Gras, Corinne, Panis, Valérie, Kaluzinski, Laure, Venant-Valery, Marjolène, Lam, You-Heng, Vallee, Laura, Riviere, Frédéric, Durand, Muriel, Benghadid, Dihya, Villeneuve, Emilie, Hentic Dhome, Olivia, Laurent, Lucie, Bounouar, Zedjiga, De Mestier, Louis, Dubois, Jacqueline, Eyriey, Magali, Moreau, Lionel, Ahle, Guido, Baihas, Dib, Aldabbagh, Kaïs, Degriffolet, Dominique, Sebbagh, Virginie, Seghezzi, Jean-Christophe, Lozach-Brugirard, Marion, Mandrou, Julie, Mavier, Loubna, Hennetier, Florence, Wagner, Jean-Philippe, Carola, Elisabeth, Chandirakumaran, Karthiga, Loutski, Sandrine, Cojean-Zelek, Isabelle, Bouras, Amina, Lacour, Sandrine, Froura, Fahem, Ben Nadji, Hadjer, Cattelain, Sophie, Darloy, Franck, Jolimoy Boilleau, Geneviève, Maissiat, Cyrielle, Darut-Jouve, Ariane, Lorgis, Véronique, Charifi-Alaoui, Ikram, Ghiringhelli, François, Drouillard, Antoine, Chaix, Marie, Manfredi, Sylvain, Lepage, Côme, Gagnaire, Alice, Latournerie, Marianne, jourdan, Sofia, Perrot, Nora, folia, Mireille, Minello, Anne, Jouve, Jean-Louis, Fery, Marielle, Landau, Alain, Evrard, Diane, Valenza, Bruno, Paitel, Jean-François, Chablais, Laetitia, Kreitmann, Thomas, Lancry-Lecomte, Laurence, Monard, Adrien, Faugeras, Eve, Boucheret, Paul, Glommeau, Cécile, Tchikladze, Christine, Garnier Tixidre, Claire, Long, Jérôme, Zaidi, Manel, Delabarre, Véronique, Meyzenc, Juliette, Ferrand, Loïc, Moro-Sibilot, Denis, Bouheret, Paul, Leyronnas, Cécile, Herve, Camille, Thoor, Audrey, Jacquet, Emanuelle, Roth, Gaël, Madapathage-Senanyake, Videsheka, Chupeau, Peggy, Bieber, Elsa, Rosso, Maud, Lepage, Isabelle, Priou, Frank, Laly, Margot, Aprelon, Sylvie, Sobolak, Natacha, Homokos, Helen, Pointreau, Yoann, Watelle, Fabienne, Pham-Becker, Alice, Lauridant, Géraldine, Turpin, Anthony, Dujardin, Charlotte, Lenglin, Etienne, Nienguet Tsota, Aimée, Dominguez, Sophie, Forestier, Alexandra, Nouvel, Franck, Lerooy, Justine, Ratajczak, Céline, Romano, Olivier, Brzyski, Dorothéee, Barriere, Aurélien, Genet, Dominique, Tisse, Julien, Zasadny, Xavier, Grelet, Adeline, Hennion-Imbault, Amélie, Haustraete, Eglantine, Louafi, Samy, Awad, Manal, Zekri, Younes, Cheneau, Caroline, Leissen, Nolwen, Egreteau, Joëlle, Breant, Alexandra, Sarabi, Matthieu, Labonne, Stéphanie, Forestier, Julien, Leclercq, Céline, Prunier-Bossion, Florence, Ray Coquard, Isabelle, Guillet, Marielle, Theillaumas, Aurélie, Prome, Emilie, Walter, Thomas, Philouze, Pierre, Lawo, Melody, De Talhouet, Solène, Beuvelot, Johanne, Molin, Yann, Bellecoste Martin, Marie, Saussereau, Maud, Agnelli, Lauren, Fakhry, Nicolas, Laplace, Christophe, Norguet Monnereau, Emmanuelle, Boucard, Céline, Djenad, Kahina, Fontaine, Catherine, Seitz, Jean-François, Dahan, Laétitia, Sigrand, Julie, Duluc, Muriel, Locher, Christophe, Fleury, Marjory, Brou Marie, Ange, Berkane, Ramdane, Poupblanc, Séverine, Auby, Dominique, Petran, Daniela, Texereau, Patrick, Guerineau, Elodie, Andre, Morgan, Mahjoubi, Linda, Sarrazin, Fanny, Jeanson, Sonia, Gschwend, Anthony, Birr, Virginie, Debieuvre, Didier, Fore, Mathieu, Noirclerc, Monique, Dahou, Sihem, Spaeth, Dominique, Lambotin, Mélanie, Lelu, Thomas, Linot, Benjamin, Hugon, Nathalie, Rousseau, Dominique, Castanie, Hélène, Lenne, Carole, Lortholary, Alain, Cessot, Anatole, Merzoug, Messaouda, Naudin, Cécile, Vannetzel, Jean-Michel, Aziz, Ghina, Hadj Arab, Yacine, Pernes, Stéphanie, Roche-Lachaise, Isabelle, Fiteni, Frédéric, Yahiaoui, Hadjer, Marel Lopez, Gwendoline, Oddoz, Jeanne, Peira, Fabienne, Michel, Olivier, Meunier, Jérôme, Ouahrani, Brahim, Roger, Antoine, Branco, Sonia, Nguyen, Van, Gisselbrecht, Mathilde, Hammad, Ghania, Mordant, Pierre, Stroksztejn, Magda, Pocard, Marc, Nlo Meyengue, Luc, Aparicio, Thomas, Sacco, Emmanuelle, Simon Anne, Sophie, Fabre-Guillevin, Elizabeth, Wislez, Marie, Slim, Marine, Zaanan, Aziz, Cadranel, Jacques, Pluvy, Johan, Ursu, Rénata, Geraldo, Amyrath, Lihi, Rime, Vo, Maryline, Brouk, Zohra, Colle, Raphaël, Bennamoun, Mostefa, Lacan, Fabrice, Louvet, Christophe, Mebarki, Soraya, Veyri, Marianne, Paillaud, Elena, Lucas, Christelle, Dubreuil, Olivier, Lyamani, Jamila, Idbaih, Ahmed, Agguini, Hanane, Soularue, Emilie, Canellas, Anthony, Zalcman, Gérard, Jourdaine, Clément, Verillaud, Benjamin, Herzine, Hakima, Raymond, Eric, Mathiot, Nathalie, Palmieri, Lola Jade, Epanya, Christian, Taieb, Julien, Bertrand, Eliane, Goujon, Gaël, Namour, Céline, Gazeau, Benoit, Zafirova, Biljana, Mirghani, Haitham, Belin, Catherine, Belkhir, Kahina, Gharib, Myriam, Vozy, Aurore, Amrane, Karim, Spano, Jean-Philippe, Wassermann, Johanna, Feuvret, Loic, Bachet, Jean-Baptiste, Philonenko, Sara, Guillot, Laetitia, Zabbe, Marion, Gibiat, Stéphanie, Baylot, Camille, Jouinot, Aude, Leduc, Nicolas, Vieillot, Sabine, James, Laurie, Ducerf, Camille, Blanc, Jean-Frédéric, Falandry Leger, Claire, Wautot, Virginie, Chauvenet, Marion, Vincent, Aude, Tougeron, David, Goulvent, Sandrine, Suc, Etienne, Laurenty, Anne-Pascale, Marquis, Eric, Bonnaire, Margaux, Dewolf, Maxime, Brenet, Esteban, Billard, Delphine, Litre, Claude-Fabien, Dumazet, Antoine, Botsen, Damien, Vazel, Marion, Carlier, Claire, Bonnerave, David, Marchand-Crety, Charles, Bouche, Olivier, Fosse, Patricia, Sefrioui, David, Michel, Pierre, Watson, Sarah, Neuzillet, Cindy, Torche, Fatah, Muron, Thierry, Natur, Stéphane, Desgrippes, Romain, Bihel, Véronique, Ferrand, François-Régis, Leiterer, Caroline, Lavole, Julie, Moquet, Claire, Pressoir, Nathalie, Dziukala, Catherine, Ligeza Poisson, Catherine, Naji, Abdelhalim, Williet, Nicolas, Phelip, Jean-Marc, Di Palma, Fabrice, Kherrour Mehdi, Amina, Langrand-Escure, Julien, Fournel, Pierre, Pigne, Grégoire, Saban-Roche, Léa, Magne, Nicolas, Vassal, Cécile, Jacquin, Jean-Philippe, Ramirez, Carole, Vallard, Alexis, Collard, Olivier, Rivoirard, Romain, Graber, Ivan, Trager Maury, Stéphanie, Duboisset, Elodie, Ayllon Ugarte, Jorge, Rami, Dalilia, Saler, Christine, Reinbolt, Manon, Le Fevre, Clara, Ben Abdelghani, Meher, Dourthe, Louis-Marie, Perruisseau-Carrier, Joffrey, Nguimpi-Tambou, Marlène, Barret, Flavie, Di Stefano Anna, Luisa, Balthazard, Annie, Mabro, May, Vassord-Dang, Camille, Le Marchand, Mathilde, Vergniol, Julien, Pripon, Iulia, Daemaegdt, Axelle, Latry, Vanessa, Larrieu, Muna, Landry, Gaëlle, Touihri Maximin, Laetitia, Del Piano, Francesco, Barlet, Agnès, Vernisse, Mylène, Lafond, Sophie, Genin, Charline, Sibertin-Blanc, Camille, Chabrillac, Emilien, Gregoire, Caroline, Vergez, Sébastien, Panouille, Quentin, Guimbaud, Rosine, Richa, Floriane, Lebellec, Loïc, Gounin, Sophie, Buiret, Guillaume, Baudin, Marine, Hamon, Hervé, Deshorgue, Anne-Claire, Barrascout, Eduardo, Legrand, Stéphanie, Houlze, Morgane, Cambula, Linda, Lopez, Anthony, Fouquet, Guillaume, Touabi, Kahina, GermaIn, Adeline, Godbert, Benoit, Voivret, Florence, Perrin, Julie, Da Silva, Rosa, Bernichon, Emilie, Lièvre, Astrid, Ray-Coquard, Isabelle, Le Malicot, Karine, Paoletti, Xavier, Bouché, Olivier, Aldabbagh, Kais, Colle, Raphael, Hardy-Bessard, Anne-Claire, Colomba, Emeline, Bourhis, Jean, Gorphe, Philippe, Ursu, Renata, and Di Stefano, Anna Luisa

Published
2020
Full Text
View/download PDF

16. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Author

Lundqvist, Andreas, van Hoef, Vincent, Zhang, Xiaonan, Wennerberg, Erik, Lorent, Julie, Witt, Kristina, Sanz, Laia Masvidal, Liang, Shuo, Murray, Shannon, Larsson, Ola, Kiessling, Rolf, Mao, Yumeng, Sidhom, John-William, Bessell, Catherine A, Havel, Jonathan, Schneck, Jonathan, Chan, Timothy A, Sachsenmeier, Eliot, Woods, David, Berglund, Anders, Ramakrishnan, Rupal, Sodre, Andressa, Weber, Jeffrey, Zappasodi, Roberta, Li, Yanyun, Qi, Jingjing, Wong, Philip, Sirard, Cynthia, Postow, Michael, Newman, Walter, Koon, Henry, Velcheti, Vamsidhar, Callahan, Margaret K, Wolchok, Jedd D, Merghoub, Taha, Lum, Lawrence G, Choi, Minsig, Thakur, Archana, Deol, Abhinav, Dyson, Gregory, Shields, Anthony, Haymaker, Cara, Uemura, Marc, Murthy, Ravi, James, Marihella, Wang, Daqing, Brevard, Julie, Monaghan, Catherine, Swann, Suzanne, Geib, James, Cornfeld, Mark, Chunduru, Srinivas, Agrawal, Sudhir, Yee, Cassian, Wargo, Jennifer, Patel, Sapna P, Amaria, Rodabe, Tawbi, Hussein, Glitza, Isabella, Woodman, Scott, Hwu, Wen-Jen, Davies, Michael A, Hwu, Patrick, Overwijk, Willem W, Bernatchez, Chantale, Diab, Adi, Massarelli, Erminia, Segal, Neil H, Ribrag, Vincent, Melero, Ignacio, Gangadhar, Tara C, Urba, Walter, Schadendorf, Dirk, Ferris, Robert L, Houot, Roch, Morschhauser, Franck, Logan, Theodore, Luke, Jason J, Sharfman, William, Barlesi, Fabrice, Ott, Patrick A, Mansi, Laura, Kummar, Shivaani, Salles, Gilles, Carpio, Cecilia, Meier, Roland, Krishnan, Suba, McDonald, Dan, Maurer, Matthew, Gu, Xuemin, Neely, Jaclyn, Suryawanshi, Satyendra, Levy, Ronald, Khushalani, Nikhil, Wu, Jennifer, Zhang, Jinyu, Basher, Fahmin, Rubinstein, Mark, Bucsek, Mark, and Qiao, Guanxi

Subjects
Good Health and Well Being
Published
2016

17. Les auteurs

Author

Aulagner, Gilles, primary, Cazin, Jean-Louis, additional, Lemare, François, additional, Limat, Samuel, additional, Armoiry, Xavier, additional, Astier, Alain, additional, Barbier, Garance, additional, Bardin, Christophe, additional, Boiteux-Jurain, Marie, additional, Boulin, Mathieu, additional, Brunie, Vanida, additional, Burtin, Christophe, additional, Capelle, Aude, additional, Chaigneau, Loïc, additional, Chenailler, Catherine, additional, Chinot, Olivier, additional, Clairet, Anne-Laure, additional, Correard, Florian, additional, Daguindau, Étienne, additional, Dahan, Muriel, additional, Dansin, Éric, additional, Debordeaux, Frédéric, additional, Demoré, Béatrice, additional, Desmaris, Romain, additional, Dussart, Claude, additional, Estève, Marie-Anne, additional, Fagnoni, Philippe, additional, Faucitano, Alexia, additional, Faure, Pierre, additional, Favé, Sophie, additional, Fernandez, Christine, additional, Gaillard, Claire, additional, Goldwasser, François, additional, Govindoorazoo, Axel, additional, Gueneau, Pauline, additional, Guerrini-Rousseau, Léa, additional, Guyotat, Denis, additional, Henaine, Anne-Marie, additional, Honoré, Stéphane, additional, Jary, Marine, additional, Jeannin, Marie, additional, Jonchere, Gabrielle, additional, Kalbacher, Elsa, additional, Kroemer, Marie, additional, Kuzzay, Marie-Pierre, additional, Levêque, Dominique, additional, Madelaine, Isabelle, additional, Mansi, Laura, additional, Mimoun, Aguirre, additional, Mongaret, Céline, additional, Nerich, Virginie, additional, Noirez, Véronique, additional, Penel, Nicolas, additional, Piketty, Anne-Catherine, additional, Pistre, Pauline, additional, Puisset, Florent, additional, Rizzo-Padoin, Nathalie, additional, Roy, Pétronille, additional, Sautou, Valérie, additional, Servent, Véronique, additional, Slimano, Florian, additional, Spiesser-Robelet, Laurence, additional, Thiery-Vuillemin, Antoine, additional, Thomas-Schoemann, Audrey, additional, Tournamille, Jean-François, additional, Valteau-Couanet, Dominique, additional, Vienot, Angélique, additional, Vigneron, Jean, additional, Villeminey, Clémentine, additional, Vinson, Camille, additional, Braguer, Diane, additional, Chaigneau, Aurélie, additional, Chaussard, Michaël, additional, Demirdjian, Sylvie, additional, Gaudin, Amélie, additional, Guénée de Courtivron, Charlotte, additional, Hosten, Benoît, additional, Morel, Daphné, additional, Opsomer, Marie-Agnès, additional, Petit, Marie, additional, and Pinel, Sylvine, additional

Published
2020
Full Text
View/download PDF

19. A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study

Author

Drozd, Chloé, primary, Curtit, Elsa, additional, Jacquinot, Quentin, additional, Marquine, Charlène, additional, Mansi, Laura, additional, Chaigneau, Loïc, additional, Dobi, Erion, additional, Viot, Julien, additional, Meynard, Guillaume, additional, Paillard, Marie-Justine, additional, Goujon, Morgan, additional, Roux, Pauline, additional, Vernerey, Dewi, additional, Gillet, Valérie, additional, Bourdin, Hubert, additional, Galli, Silvio, additional, Meneveau, Nathalie, additional, and Mougin, Fabienne, additional

Published
2023
Full Text
View/download PDF

20. Prévalence et prise en charge de la douleur chez les patients présentant un cancer métastatique en Franche-Comté

Author

Dénommé, Fanny, Kroemer, Marie, Montcuquet, Philippe, Nallet, Gilles, Thiery-Vuillemin, Antoine, Bazan, Fernando, Mouillet, Guillaume, Villanueva, Cristian, Demarchi, Martin, Stein, Ulrich, Almotlak, Hamadi, Chaigneau, Loïc, Curtit, Elsa, Meneveau, Nathalie, Maurina, Tristan, Dobi, Erion, Hon, Thierry Nguyen Tan, Cals, Laurent, Mansi, Laura, Verlut, Clotilde, Pana-Katatali, Héloïse, Caubet, Mathieu, Paillard, Marie-Justine, Limat, Samuel, Pivot, Xavier, and Nerich, Virginie

Published
2016
Full Text
View/download PDF

21. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, and Yunokawa, Mayu

Abstract

The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Published
2024
Full Text
View/download PDF

22. Supplementary Figure S6 from Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Author

Beziaud, Laurent, primary, Mansi, Laura, primary, Ravel, Patrice, primary, Marie-Joseph, Elodie Lauret, primary, Laheurte, Caroline, primary, Rangan, Laurie, primary, Bonnefoy, Francis, primary, Pallandre, Jean-René, primary, Boullerot, Laura, primary, Gamonet, Clémentine, primary, Vrecko, Sindy, primary, Queiroz, Lise, primary, Maurina, Tristan, primary, Mouillet, Guillaume, primary, Hon, Thierry Nguyen Tan, primary, Curtit, Elsa, primary, Royer, Bernard, primary, Gaugler, Béatrice, primary, Bayry, Jagadeesh, primary, Tartour, Eric, primary, Thiery-Vuillemin, Antoine, primary, Pivot, Xavier, primary, Borg, Christophe, primary, Godet, Yann, primary, and Adotévi, Olivier, primary

Published
2023
Full Text
View/download PDF

23. Supplementary methods from Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Author

Beziaud, Laurent, primary, Mansi, Laura, primary, Ravel, Patrice, primary, Marie-Joseph, Elodie Lauret, primary, Laheurte, Caroline, primary, Rangan, Laurie, primary, Bonnefoy, Francis, primary, Pallandre, Jean-René, primary, Boullerot, Laura, primary, Gamonet, Clémentine, primary, Vrecko, Sindy, primary, Queiroz, Lise, primary, Maurina, Tristan, primary, Mouillet, Guillaume, primary, Hon, Thierry Nguyen Tan, primary, Curtit, Elsa, primary, Royer, Bernard, primary, Gaugler, Béatrice, primary, Bayry, Jagadeesh, primary, Tartour, Eric, primary, Thiery-Vuillemin, Antoine, primary, Pivot, Xavier, primary, Borg, Christophe, primary, Godet, Yann, primary, and Adotévi, Olivier, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S1 from Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Author

Beziaud, Laurent, primary, Mansi, Laura, primary, Ravel, Patrice, primary, Marie-Joseph, Elodie Lauret, primary, Laheurte, Caroline, primary, Rangan, Laurie, primary, Bonnefoy, Francis, primary, Pallandre, Jean-René, primary, Boullerot, Laura, primary, Gamonet, Clémentine, primary, Vrecko, Sindy, primary, Queiroz, Lise, primary, Maurina, Tristan, primary, Mouillet, Guillaume, primary, Hon, Thierry Nguyen Tan, primary, Curtit, Elsa, primary, Royer, Bernard, primary, Gaugler, Béatrice, primary, Bayry, Jagadeesh, primary, Tartour, Eric, primary, Thiery-Vuillemin, Antoine, primary, Pivot, Xavier, primary, Borg, Christophe, primary, Godet, Yann, primary, and Adotévi, Olivier, primary

Published
2023
Full Text
View/download PDF

25. Supplementary figure legends from Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Author

Beziaud, Laurent, primary, Mansi, Laura, primary, Ravel, Patrice, primary, Marie-Joseph, Elodie Lauret, primary, Laheurte, Caroline, primary, Rangan, Laurie, primary, Bonnefoy, Francis, primary, Pallandre, Jean-René, primary, Boullerot, Laura, primary, Gamonet, Clémentine, primary, Vrecko, Sindy, primary, Queiroz, Lise, primary, Maurina, Tristan, primary, Mouillet, Guillaume, primary, Hon, Thierry Nguyen Tan, primary, Curtit, Elsa, primary, Royer, Bernard, primary, Gaugler, Béatrice, primary, Bayry, Jagadeesh, primary, Tartour, Eric, primary, Thiery-Vuillemin, Antoine, primary, Pivot, Xavier, primary, Borg, Christophe, primary, Godet, Yann, primary, and Adotévi, Olivier, primary

Published
2023
Full Text
View/download PDF

27. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

Author

Jacquinot, Quentin, primary, Meneveau, Nathalie, additional, Falcoz, Antoine, additional, Bouhaddi, Malika, additional, Roux, Pauline, additional, Degano, Bruno, additional, Chatot, Marion, additional, Curtit, Elsa, additional, Mansi, Laura, additional, Paillard, Marie-Justine, additional, Bazan, Fernando, additional, Chaigneau, Loïc, additional, Dobi, Erion, additional, Meynard, Guillaume, additional, Vernerey, Dewi, additional, Pivot, Xavier, additional, and Mougin, Fabienne, additional

Published
2022
Full Text
View/download PDF

28. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

Author

Rebucci-Peixoto, Magali, primary, Vienot, Angélique, additional, Adotevi, Olivier, additional, Jacquin, Marion, additional, Ghiringhelli, Francois, additional, de la Fouchardière, Christelle, additional, You, Benoit, additional, Maurina, Tristan, additional, Kalbacher, Elsa, additional, Bazan, Fernando, additional, Meynard, Guillaume, additional, Clairet, Anne-Laure, additional, Fagnoni-Legat, Christine, additional, Spehner, Laurie, additional, Bouard, Adeline, additional, Vernerey, Dewi, additional, Meurisse, Aurélia, additional, Kim, Stefano, additional, Borg, Christophe, additional, and Mansi, Laura, additional

Published
2022
Full Text
View/download PDF

32. TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Author

Leary, Alexandra, primary, Deluche, Elise, additional, Favier, Laure, additional, Paoletti, Xavier, additional, Mansi, Laura, additional, Tredan, Olivier, additional, Eberst, Lauriane, additional, De La Motte Rouge, Thibault, additional, Joly, Florence, additional, Lortholary, Alain, additional, You, Benoit, additional, Marmé, Frederik, additional, Van Gorp, Toon, additional, Floquet, Anne, additional, and Frenel, Jean-Sebastien, additional

Published
2022
Full Text
View/download PDF

33. HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice.

Author

Gassian, Noemie, primary, Paget-Bailly, Sophie, additional, Djoumakh, Oum El Kheir, additional, Mansi, Laura, additional, Dobi, Erion, additional, Bazan, Fernando, additional, Curtit, Elsa, additional, Chaigneau, Loic, additional, Meneveau, Nathalie, additional, Paillard, Marie-Justine, additional, Selmani, Zohair, additional, Viot, Julien, additional, Borg, Christophe, additional, and Meynard, Guillaume, additional

Published
2022
Full Text
View/download PDF

35. COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

Author

Kroemer, Marie, Spehner, Laurie, Vettoretti, Lucie, Bouard, Adeline, Eberst, Guillaume, Pili Floury, Sebastien, Capellier, Gilles, Lepiller, Quentin, Orillard, Emeline, Mansi, Laura, Clairet, Anne-Laure, Westeel, Virginie, Limat, Samuel, Dubois, Maxime, Malinowski, Léa, Bohard, Louis, Borg, Christophe, Chirouze, Catherine, and Bouiller, Kevin

Published
2021
Full Text
View/download PDF

36. Ki67 Assessment By qRT-PCR In OncotypeDx® Breast Recurrent Score®: Low Correlation With Immunohistochemistry Assessment of Ki67 And Prognostic Impact of Ki67 RNA Level of Expression.

Author

Selmani, Zohair, primary, Molimard, Chloé, additional, Overs, Alexis, additional, Bazan, Fernando, additional, Chaigneau, Loic, additional, Dobi, Erion, additional, Meneveau, Nathalie, additional, Mansi, Laura, additional, Paillard, Marie-Justine, additional, Meynard, Guillaume, additional, Viot, Julien, additional, Algros, Marie-Paule, additional, Borg, Christophe, additional, Feugeas, Jean-Paul, additional, Pivot, Xavier, additional, Prétet, Jean-Luc, additional, and Curtit, Elsa, additional

Published
2021
Full Text
View/download PDF

37. Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.

Author

Selmani, Zohair, primary, Molimard, Chloé, additional, Overs, Alexis, additional, Bazan, Fernando, additional, Chaigneau, Loic, additional, Dobi, Erion, additional, Meneveau, Nathalie, additional, Mansi, Laura, additional, Paillard, Marie-Justine, additional, Meynard, Guillaume, additional, Viot, Julien, additional, Algros, Marie-Paule, additional, Borg, Christophe, additional, Feugeas, Jean-Paul, additional, Pivot, Xavier, additional, Prétet, Jean-Luc, additional, and Curtit, Elsa, additional

Published
2021
Full Text
View/download PDF

38. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Author

Rebucci-Peixoto, Magali, Vienot, Angélique, Adotevi, Olivier, Jacquin, Marion, Ghiringhelli, Francois, de la Fouchardière, Christelle, You, Benoit, Maurina, Tristan, Kalbacher, Elsa, Bazan, Fernando, Meynard, Guillaume, Clairet, Anne-Laure, Fagnoni-Legat, Christine, Spehner, Laurie, Bouard, Adeline, Vernerey, Dewi, Meurisse, Aurélia, Kim, Stefano, Borg, Christophe, and Mansi, Laura

Subjects
CANCER vaccines, ATEZOLIZUMAB, TELOMERASE reverse transcriptase, TELOMERASE, IMMUNE checkpoint inhibitors, IPILIMUMAB, CETUXIMAB
Abstract

Background: There is a strong rational of using anti-programmed cell death protein-1 and its ligand (anti-PD-1/L1) antibodies in human papillomavirus (HPV)-induced cancers. However, anti-PD-1/L1 as monotherapy induces a limited number of objective responses. The development of novel combinations in order to improve the clinical efficacy of an anti-PD-1/L1 is therefore of interest. Combining anti-PD-1/L1 therapy with an antitumor vaccine seems promising in HPV-positive (+) cancers. UCPVax is a therapeutic cancer vaccine composed of two separate peptides derived from telomerase (hTERT, human telomerase reverse transcriptase). UCPVax is being evaluated in a multicenter phase I/II study in NSCLC (non-small cell lung cancer) and has demonstrated to be safe and immunogenic. The aim of the VolATIL study is to evaluate the combination of atezolizumab (an anti-PD-L1) and UCPVax vaccine in a multicenter phase II study in patients with HPV+ cancers. Methods: Patients with HPV+ cancer (anal canal, head and neck, and cervical or vulvar), at locally advanced or metastatic stage, and refractory to at least one line of systemic chemotherapy are eligible. The primary end point is the objective response rate (ORR) at 4 months. Patients will receive atezolizumab every 3 weeks at a fixed dose of 1,200 mg in combination with the UCPVax vaccine at 1 mg subcutaneously. Discussion: Anti-cancer vaccines can restore cancer-immunity via the expansion and activation of tumor-specific T cells in patients lacking pre-existing anti-tumor responses. Moreover, preclinical data showed that specific TH1 CD4 T cells sustain the quality and homing of an antigen-specific CD8+ T-cell immunity. In previous clinical studies, the induction of anti-hTERT immunity was significantly correlated to survival in patients with advanced squamous anal cell carcinoma. Thus, there is a strong rational to combine an anti-cancer hTERT vaccine and an immune checkpoint inhibitor to activate and promote antitumor T-cell immunity. This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a telomerase-based TH1 inducing vaccine (UCPVax) and an anti-PD-L1 (atezolizumab) immunotherapy in HPV+ cancers, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Lièvre, Astrid, primary, Turpin, Anthony, additional, Ray-Coquard, Isabelle, additional, Le Malicot, Karine, additional, Thariat, Juliette, additional, Ahle, Guido, additional, Neuzillet, Cindy, additional, Paoletti, Xavier, additional, Bouché, Olivier, additional, Aldabbagh, Kais, additional, Michel, Pierre, additional, Debieuvre, Didier, additional, Canellas, Anthony, additional, Wislez, Marie, additional, Laurent, Lucie, additional, Mabro, May, additional, Colle, Raphael, additional, Hardy-Bessard, Anne-Claire, additional, Mansi, Laura, additional, Colomba, Emeline, additional, Bourhis, Jean, additional, Gorphe, Philippe, additional, Pointreau, Yoann, additional, Idbaih, Ahmed, additional, Ursu, Renata, additional, Di Stefano, Anna Luisa, additional, Zalcman, Gérard, additional, Aparicio, Thomas, additional, Moulin, Solenne, additional, Leleu, Olivier, additional, Leparree, Sylvie, additional, Goasdoue, Henri, additional, Piprot, Christine, additional, Tourneur, Gerald, additional, Bayart, Vincent, additional, Lignier, Delphine, additional, Lachaier, Emma, additional, Khamari, Marwa, additional, Coutte, Alexandre, additional, Siembida, Nicolas, additional, Houessinon, Aline, additional, Regimbeau, Jean Marc, additional, Chauffert, Bruno, additional, Moreira, Aurélie, additional, Hautefeuille, Vincent, additional, Hee, Christine, additional, Boone, Mathieu, additional, Bihan, Céline, additional, Chive, Emilie, additional, Poulet-Potriquier, Stéphane, additional, Fahem, Rachida, additional, Luet, Dominique, additional, Roquin, Guillaume, additional, Vitellius, Carole, additional, Cornet-Trichereau, Nathanaëlle, additional, Caroli-Bosc, François-Xavier, additional, Thirot-Bidault, Anne, additional, Ropert, Stanislas, additional, Gachet - Masson, Julie, additional, Dehais, Mélanie, additional, L'helgoualc'h, Gwen-Ael, additional, Ali-Mahamadou, Ibrahim, additional, Talfi, Safia, additional, Belmont, Laure, additional, Kilendo, Dieudonné, additional, Benrezzak, Nasro, additional, Dubief, Emeline, additional, Conroy, Guillaume, additional, Delique, Laurence, additional, Basso, Maud, additional, Pons, Isabelle, additional, Salignon, Karine, additional, Villing, Anne-Laure, additional, Mougenot, Emmanuelle, additional, Porebski, Cassandra, additional, Guiatni, Asma, additional, Cloarec, Nicolas, additional, Mineur, Laurent, additional, Bouchaud, Marie, additional, David, Céleste, additional, Peytier, Annie, additional, Greletty, Thomas, additional, Audemar, Franck, additional, Vignes, Emanuelle, additional, Minne, Floriane, additional, Goldzak, Guillaume, additional, Huysman, Fabienne, additional, Hocine, Fayçal, additional, Lakkis, Zaher, additional, Meynard, Guillaume, additional, Almotlak, Hamadi, additional, Klajer, Elodie, additional, Sun, Xu-Shan, additional, Wasselin, Julie, additional, Catala, Pascale, additional, Mazuy, Claire, additional, Vandamme, Hélène, additional, Prevost, Jean-Briac, additional, Fadin, Aurélie, additional, Basson, Laurent, additional, Huguet, Jean-Baptiste, additional, Dos Santos, Emmanuelle, additional, Jany, Bérangère, additional, Saad, Alain, additional, Goutorbe, Frédéric, additional, Oziol, Eric, additional, Ramdani, Mohamed, additional, Kadiri, Ouafae, additional, Garbay, Delphine, additional, Huet, Clotilde, additional, Giroux Leprieur, Etienne, additional, Teng, Wen, additional, Monvoisin, Justine, additional, Arnaud Coffin, Patrick, additional, Roux, Sylvie, additional, Orfeuvre, Hubert, additional, Chagros, Mélanie, additional, Pillon, Didier, additional, Rassoul, Agathe, additional, Poureau, Pierre Guillaume, additional, Novello, Cécile, additional, Ducray, François, additional, Trouba, Cécile, additional, Bastit, Vianney, additional, Babin, Emmanuel, additional, Leon, Vincent, additional, Courtecuisse, Anne-Catherine, additional, Vambre, Julie, additional, Tack, Vincent, additional, Desauw, Christophe, additional, Meniai, Fatima, additional, Peres, Christina, additional, Esparcieux, Aurélie, additional, Perrier, Hervé, additional, Doux, Nathalie, additional, Kaphan, Régis, additional, Roques, Bertrand, additional, Rebischung, Christine, additional, Mille, Dominique, additional, Fernandes, Gaëlle, additional, Abdelli, Naceur, additional, Jousset, Natacha, additional, Combe, Pierre, additional, Jonveaux, Eric, additional, Dumont, Patrick, additional, Kanaan, Marc, additional, Berthelot Gras, Corinne, additional, Panis, Valérie, additional, Kaluzinski, Laure, additional, Venant-Valery, Marjolène, additional, Lam, You-Heng, additional, Vallee, Laura, additional, Riviere, Frédéric, additional, Durand, Muriel, additional, Benghadid, Dihya, additional, Villeneuve, Emilie, additional, Hentic Dhome, Olivia, additional, Bounouar, Zedjiga, additional, De Mestier, Louis, additional, Dubois, Jacqueline, additional, Eyriey, Magali, additional, Moreau, Lionel, additional, Baihas, Dib, additional, Aldabbagh, Kaïs, additional, Degriffolet, Dominique, additional, Sebbagh, Virginie, additional, Seghezzi, Jean-Christophe, additional, Lozach-Brugirard, Marion, additional, Mandrou, Julie, additional, Mavier, Loubna, additional, Hennetier, Florence, additional, Wagner, Jean-Philippe, additional, Carola, Elisabeth, additional, Chandirakumaran, Karthiga, additional, Loutski, Sandrine, additional, Cojean-Zelek, Isabelle, additional, Bouras, Amina, additional, Lacour, Sandrine, additional, Froura, Fahem, additional, Ben Nadji, Hadjer, additional, Cattelain, Sophie, additional, Darloy, Franck, additional, Jolimoy Boilleau, Geneviève, additional, Maissiat, Cyrielle, additional, Darut-Jouve, Ariane, additional, Lorgis, Véronique, additional, Charifi-Alaoui, Ikram, additional, Ghiringhelli, François, additional, Drouillard, Antoine, additional, Chaix, Marie, additional, Manfredi, Sylvain, additional, Lepage, Côme, additional, Gagnaire, Alice, additional, Latournerie, Marianne, additional, jourdan, Sofia, additional, Perrot, Nora, additional, folia, Mireille, additional, Minello, Anne, additional, Jouve, Jean-Louis, additional, Fery, Marielle, additional, Landau, Alain, additional, Evrard, Diane, additional, Valenza, Bruno, additional, Paitel, Jean-François, additional, Chablais, Laetitia, additional, Kreitmann, Thomas, additional, Lancry-Lecomte, Laurence, additional, Monard, Adrien, additional, Faugeras, Eve, additional, Boucheret, Paul, additional, Glommeau, Cécile, additional, Tchikladze, Christine, additional, Garnier Tixidre, Claire, additional, Long, Jérôme, additional, Zaidi, Manel, additional, Delabarre, Véronique, additional, Meyzenc, Juliette, additional, Ferrand, Loïc, additional, Moro-Sibilot, Denis, additional, Bouheret, Paul, additional, Leyronnas, Cécile, additional, Herve, Camille, additional, Thoor, Audrey, additional, Jacquet, Emanuelle, additional, Roth, Gaël, additional, Madapathage-Senanyake, Videsheka, additional, Chupeau, Peggy, additional, Bieber, Elsa, additional, Rosso, Maud, additional, Lepage, Isabelle, additional, Priou, Frank, additional, Laly, Margot, additional, Aprelon, Sylvie, additional, Sobolak, Natacha, additional, Homokos, Helen, additional, Watelle, Fabienne, additional, Pham-Becker, Alice, additional, Lauridant, Géraldine, additional, Dujardin, Charlotte, additional, Lenglin, Etienne, additional, Nienguet Tsota, Aimée, additional, Dominguez, Sophie, additional, Forestier, Alexandra, additional, Nouvel, Franck, additional, Lerooy, Justine, additional, Ratajczak, Céline, additional, Romano, Olivier, additional, Brzyski, Dorothéee, additional, Barriere, Aurélien, additional, Genet, Dominique, additional, Tisse, Julien, additional, Zasadny, Xavier, additional, Grelet, Adeline, additional, Hennion-Imbault, Amélie, additional, Haustraete, Eglantine, additional, Louafi, Samy, additional, Awad, Manal, additional, Zekri, Younes, additional, Cheneau, Caroline, additional, Leissen, Nolwen, additional, Egreteau, Joëlle, additional, Breant, Alexandra, additional, Sarabi, Matthieu, additional, Labonne, Stéphanie, additional, Forestier, Julien, additional, Leclercq, Céline, additional, Prunier-Bossion, Florence, additional, Ray Coquard, Isabelle, additional, Guillet, Marielle, additional, Theillaumas, Aurélie, additional, Prome, Emilie, additional, Walter, Thomas, additional, Philouze, Pierre, additional, Lawo, Melody, additional, De Talhouet, Solène, additional, Beuvelot, Johanne, additional, Molin, Yann, additional, Bellecoste Martin, Marie, additional, Saussereau, Maud, additional, Agnelli, Lauren, additional, Fakhry, Nicolas, additional, Laplace, Christophe, additional, Norguet Monnereau, Emmanuelle, additional, Boucard, Céline, additional, Djenad, Kahina, additional, Fontaine, Catherine, additional, Seitz, Jean-François, additional, Dahan, Laétitia, additional, Sigrand, Julie, additional, Duluc, Muriel, additional, Locher, Christophe, additional, Fleury, Marjory, additional, Brou Marie, Ange, additional, Berkane, Ramdane, additional, Poupblanc, Séverine, additional, Auby, Dominique, additional, Petran, Daniela, additional, Texereau, Patrick, additional, Guerineau, Elodie, additional, Andre, Morgan, additional, Mahjoubi, Linda, additional, Sarrazin, Fanny, additional, Jeanson, Sonia, additional, Gschwend, Anthony, additional, Birr, Virginie, additional, Fore, Mathieu, additional, Noirclerc, Monique, additional, Dahou, Sihem, additional, Spaeth, Dominique, additional, Lambotin, Mélanie, additional, Lelu, Thomas, additional, Linot, Benjamin, additional, Hugon, Nathalie, additional, Rousseau, Dominique, additional, Castanie, Hélène, additional, Lenne, Carole, additional, Lortholary, Alain, additional, Cessot, Anatole, additional, Merzoug, Messaouda, additional, Naudin, Cécile, additional, Vannetzel, Jean-Michel, additional, Aziz, Ghina, additional, Hadj Arab, Yacine, additional, Pernes, Stéphanie, additional, Roche-Lachaise, Isabelle, additional, Fiteni, Frédéric, additional, Yahiaoui, Hadjer, additional, Marel Lopez, Gwendoline, additional, Oddoz, Jeanne, additional, Peira, Fabienne, additional, Michel, Olivier, additional, Meunier, Jérôme, additional, Ouahrani, Brahim, additional, Roger, Antoine, additional, Branco, Sonia, additional, Nguyen, Van, additional, Gisselbrecht, Mathilde, additional, Hammad, Ghania, additional, Mordant, Pierre, additional, Stroksztejn, Magda, additional, Pocard, Marc, additional, Nlo Meyengue, Luc, additional, Sacco, Emmanuelle, additional, Simon Anne, Sophie, additional, Fabre-Guillevin, Elizabeth, additional, Slim, Marine, additional, Zaanan, Aziz, additional, Cadranel, Jacques, additional, Pluvy, Johan, additional, Ursu, Rénata, additional, Geraldo, Amyrath, additional, Lihi, Rime, additional, Vo, Maryline, additional, Brouk, Zohra, additional, Colle, Raphaël, additional, Bennamoun, Mostefa, additional, Lacan, Fabrice, additional, Louvet, Christophe, additional, Mebarki, Soraya, additional, Veyri, Marianne, additional, Paillaud, Elena, additional, Lucas, Christelle, additional, Dubreuil, Olivier, additional, Lyamani, Jamila, additional, Agguini, Hanane, additional, Soularue, Emilie, additional, Jourdaine, Clément, additional, Verillaud, Benjamin, additional, Herzine, Hakima, additional, Raymond, Eric, additional, Mathiot, Nathalie, additional, Palmieri, Lola Jade, additional, Epanya, Christian, additional, Taieb, Julien, additional, Bertrand, Eliane, additional, Goujon, Gaël, additional, Namour, Céline, additional, Gazeau, Benoit, additional, Zafirova, Biljana, additional, Mirghani, Haitham, additional, Belin, Catherine, additional, Belkhir, Kahina, additional, Gharib, Myriam, additional, Vozy, Aurore, additional, Amrane, Karim, additional, Spano, Jean-Philippe, additional, Wassermann, Johanna, additional, Feuvret, Loic, additional, Bachet, Jean-Baptiste, additional, Philonenko, Sara, additional, Guillot, Laetitia, additional, Zabbe, Marion, additional, Gibiat, Stéphanie, additional, Baylot, Camille, additional, Jouinot, Aude, additional, Leduc, Nicolas, additional, Vieillot, Sabine, additional, James, Laurie, additional, Ducerf, Camille, additional, Blanc, Jean-Frédéric, additional, Falandry Leger, Claire, additional, Wautot, Virginie, additional, Chauvenet, Marion, additional, Vincent, Aude, additional, Tougeron, David, additional, Goulvent, Sandrine, additional, Suc, Etienne, additional, Laurenty, Anne-Pascale, additional, Marquis, Eric, additional, Bonnaire, Margaux, additional, Dewolf, Maxime, additional, Brenet, Esteban, additional, Billard, Delphine, additional, Litre, Claude-Fabien, additional, Dumazet, Antoine, additional, Botsen, Damien, additional, Vazel, Marion, additional, Carlier, Claire, additional, Bonnerave, David, additional, Marchand-Crety, Charles, additional, Bouche, Olivier, additional, Fosse, Patricia, additional, Sefrioui, David, additional, Watson, Sarah, additional, Torche, Fatah, additional, Muron, Thierry, additional, Natur, Stéphane, additional, Desgrippes, Romain, additional, Bihel, Véronique, additional, Ferrand, François-Régis, additional, Leiterer, Caroline, additional, Lavole, Julie, additional, Moquet, Claire, additional, Pressoir, Nathalie, additional, Dziukala, Catherine, additional, Ligeza Poisson, Catherine, additional, Naji, Abdelhalim, additional, Williet, Nicolas, additional, Phelip, Jean-Marc, additional, Di Palma, Fabrice, additional, Kherrour Mehdi, Amina, additional, Langrand-Escure, Julien, additional, Fournel, Pierre, additional, Pigne, Grégoire, additional, Saban-Roche, Léa, additional, Magne, Nicolas, additional, Vassal, Cécile, additional, Jacquin, Jean-Philippe, additional, Ramirez, Carole, additional, Vallard, Alexis, additional, Collard, Olivier, additional, Rivoirard, Romain, additional, Graber, Ivan, additional, Trager Maury, Stéphanie, additional, Duboisset, Elodie, additional, Ayllon Ugarte, Jorge, additional, Rami, Dalilia, additional, Saler, Christine, additional, Reinbolt, Manon, additional, Le Fevre, Clara, additional, Ben Abdelghani, Meher, additional, Dourthe, Louis-Marie, additional, Perruisseau-Carrier, Joffrey, additional, Nguimpi-Tambou, Marlène, additional, Barret, Flavie, additional, Di Stefano Anna, Luisa, additional, Balthazard, Annie, additional, Vassord-Dang, Camille, additional, Le Marchand, Mathilde, additional, Vergniol, Julien, additional, Pripon, Iulia, additional, Daemaegdt, Axelle, additional, Latry, Vanessa, additional, Larrieu, Muna, additional, Landry, Gaëlle, additional, Touihri Maximin, Laetitia, additional, Del Piano, Francesco, additional, Barlet, Agnès, additional, Vernisse, Mylène, additional, Lafond, Sophie, additional, Genin, Charline, additional, Sibertin-Blanc, Camille, additional, Chabrillac, Emilien, additional, Gregoire, Caroline, additional, Vergez, Sébastien, additional, Panouille, Quentin, additional, Guimbaud, Rosine, additional, Richa, Floriane, additional, Lebellec, Loïc, additional, Gounin, Sophie, additional, Buiret, Guillaume, additional, Baudin, Marine, additional, Hamon, Hervé, additional, Deshorgue, Anne-Claire, additional, Barrascout, Eduardo, additional, Legrand, Stéphanie, additional, Houlze, Morgane, additional, Cambula, Linda, additional, Lopez, Anthony, additional, Fouquet, Guillaume, additional, Touabi, Kahina, additional, GermaIn, Adeline, additional, Godbert, Benoit, additional, Voivret, Florence, additional, Perrin, Julie, additional, Da Silva, Rosa, additional, and Bernichon, Emilie, additional

Published
2020
Full Text
View/download PDF

41. Association of reinvigoration of circulating anti-telomerase CD4 Th1 response in cancer patients with anti-PD-1 response.

Author

Orillard, Emeline, primary, Boullerot, Laura, additional, Laheurte, Caroline, additional, Martin, Amandine, additional, Jacquin, Marion, additional, Berthod, Diane, additional, Ramseyer, Mélanie, additional, Jacoulet, Pascale, additional, Lahourcade, Jean, additional, Gainet Brun, Marie, additional, Almotlak, Hamadi, additional, Puzenat, Eve, additional, Nardin, Charlee, additional, Eberst, Guillaume, additional, Guion-Dusserre, Marc, additional, Mansi, Laura, additional, Aubin, Francois, additional, Westeel, Virginie, additional, Borg, Christophe, additional, and Adotevi, Olivier, additional

Published
2020
Full Text
View/download PDF

42. Monitoring of the immuno modulation resulting from the mTOR inhibitors to improve their effectiveness in cancerology

Author

Mansi, Laura, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Bourgogne Franche-Comté, and Xavier Pivot

Subjects
Mtor, Immunité T, T immunity, [SDV.IMM]Life Sciences [q-bio]/Immunology, Imunosuppression, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cancer
Abstract

The key role of the mTOR (mammalian Target of Rapamycin) pathway in cellular homeostasis raises a real interest in many therapeutics areas. Inhibitors of mTOR (mTORi) are used for graft rejection prevention to inhibit the T lymphocyte (LT) activation and induce regulatory T cells (LTreg). In cancerology, they are used for their antiproliferative and antiangiogenic actions. However, the clinical efficacy of those treatments is low. Although several mTORi resistance mechanisms linked to the tumor cell have been identified, their impact on the immune system appears as a key factor in their efficiency. Thus, our hypothesis is that the clinical efficacy of mTORi could also be dependent of an anti-tumoral immunity modulation resulting from those treatments.We performed an immunomonitoring of the Treg rate and the tumor specific Th1 anti-tumor response among a prospective cohort of patients with a metastatic renal carcinoma treated by everolimus (mTORi). We observed that the Treg rate and the suppressive function increase after the second month of treatment for almost all the patients. Paradoxically, an increase of the Th1 anti-tumoral response has also been observed for these patients. At disease progression, a majority of the patients has shown an important increase of Treg with a decrease of the Th1 response. Thus, we have been able to define different immune profiles based on the modulation of these two parameters. Progression free survival of patients with an earlier decrease of Treg and an increase of Th1 response was significantly longer compared to other patients (13.2 vs 4 months p=0.02). This immunomodulation has been consistently confirmed with patients affected by neuroendocrine tumor and treated with everolimus. The treatment impact on Treg and the Th1 response was not related to the pharmacokinetic of the drug. Thereafter, we have studied in vivo the impact of mTORi on the anti-tumoral immune response with mice affected by different tumors. We have observed the same increase of Treg in mice treated with mTORi as the increase observed in the patients. Thus, using antibodies depleting the Treg or transgenic mice allowed us to confirm the deleterious role of Treg on the anti-tumor mTORi efficacy. Those results strongly suggest that mTORi have a double effect on the immune system, a harmful impact by the induction of an immunosuppressive environment and a positive impact by the increase of the anti-tumor Th1 response.In a second time, we have studied the positive effect of mTORi on the immune system in order to optimize the anti-tumoral immunotherapies. We have shown that the administration of temsirolimus (mTORi) improves the anti-tumoral efficiency of a therapeutic vaccination on mice. Indeed, the synergic effect of this combination is tied with an augmentation of tumor infiltrate anti-tumor T CD8 with a central memory phenotype. The efficiency of this combination has been greatly improved by the addition of an antagonist CCR4 allowing the elimination of Treg generated by temsirolimus.In conclusion, mTORi remain a promising strategy in cancerology even if their use is likely to be reduced as new immunotherapies such as checkpoint inhibitors (renal carcinoma) or other targeted therapies (cycline dependent kinase inhibitors in breast cancer) appeared. In the future, the development of mTORi must integrate biomarkers taking into account the impact of these treatments on the immune system, and therapeutic combination such as the immunotherapy; Le rôle central de la voie mTOR (mammalian Target Of Rapamycin) dans l’homéostasie cellulaire suscite un réel intérêt dans de nombreux domaines thérapeutiques. Les inhibiteurs de mTOR (mTORi) sont utilisés en prévention du rejet de greffe par leur action d’inhibition de l’activation lymphocytaire T et l’induction de lymphocytes T régulateurs (Treg). En cancérologie, les mTORi sont utilisés pour leur action anti-proliférative et anti-angiogénique. Cependant, l’efficacité clinique de ces traitements reste modeste. Bien que des mécanismes de résistance aux mTORi intrinsèques à la cellule tumorale ont été identifiés, leur impact sur le système immunitaire émerge comme un facteur essentiel dans leur efficacité. Notre hypothèse est donc que l’efficacité anti-tumorale des mTORi serait également liée à la modulation de l’immunité anti-tumorale induite par ces traitements.Nous avons réalisé un immunomonitoring, du taux de Treg et de la réponse lymphocytaire Th1 anti-tumorale au sein d’une cohorte prospective de patients atteints de cancer rénal métastatique traités par éverolimus (mTORi).Nous avons observé une augmentation des Treg et de leur fonction suppressive à partir du 2ème mois de traitement dans la quasi-totalité des patients. Paradoxalement, une augmentation des réponses Th1 anti-tumorales a également été observée chez ces patients. Au moment de la progression tumorale, la majorité des patients ont présenté une forte augmentation des Treg associée à une perte de la réponse Th1. Ainsi, nous avons pu définir différents profils immunitaires basés sur la modulation de ces deux paramètres. Les patients présentant une diminution précoce des Treg associée à une augmentation de la réponse Th1 avaient une meilleure survie sans progression par rapport aux autres patients (13.2 vs 4 mois p= 0.02). De façon consistante, cette immunomodulation a été confirmée chez des patients atteints de tumeur neuroendocrine traités par éverolimus. De plus, l’impact du traitement sur les Treg et la réponse Th1 n’était pas influencé par la pharmacocinétique du médicament. Par la suite, nous avons étudié in vivo, chez des souris porteuses de différentes tumeurs, l’impact des mTORi sur la réponse immunitaire anti-tumorale. Comme chez les patients, nous avons observé une augmentation des Treg chez les souris traitées par mTORi. Ainsi, l’utilisation d’anticorps déplétants les Treg ou de souris transgéniques ont permis de démontrer le rôle délétère des Treg sur l’efficacité anti-tumorale des mTORi. Ces résultats suggèrent fortement que les mTORi ont un double effet sur le système immunitaire dans un contexte tumoral, un premier néfaste par l’induction d’un environnement immunosuppresseur et le second positif par l’augmentation d’une réponse Th1 anti-tumorale.Dans un deuxième travail, nous avons exploré l’effet positif des mTORi sur le système immunitaire afin d’optimiser les immunothérapies anti-tumorales. Nous avons montré que l’administration de temsirolimus (mTORi) améliore l’efficacité anti-tumorale d’un vaccin thérapeutique chez la souris. L’effet synergique de cette combinaison était lié à une augmentation de l’infiltration tumorale des LT CD8 anti-tumoraux de phénotype centro-mémoire. L’efficacité de cette combinaison a été nettement améliorée par l’addition d’un antagoniste de CCR4 permettant d’éliminer les Treg induits par le temsirolimus.En conclusion, les mTORi demeurent une stratégie prometteuse en cancérologie malgré la réduction de leur utilisation due à l’arrivée des nouvelles immunothérapies, comme les checkpoints inhibiteurs (notamment dans le cancer du rein) et d’autres thérapies ciblées (inhibiteurs de cycline dans le cancer du sein). En revanche, le futur développement des mTORi devra s’appuyer sur des biomarqueurs prenant en compte l’impact de ces traitements sur le système immunitaire et sur des combinaisons thérapeutiques notamment avec les immunothérapies

Published
2017

43. ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes

Author

Claude-Taupin, Aurore, primary, Fonderflick, Leïla, additional, Gauthier, Thierry, additional, Mansi, Laura, additional, Pallandre, Jean-René, additional, Borg, Christophe, additional, Perez, Valérie, additional, Monnien, Franck, additional, Algros, Marie-Paule, additional, Vigneron, Marc, additional, Adami, Pascale, additional, Delage-Mourroux, Régis, additional, Peixoto, Paul, additional, Herfs, Michael, additional, Boyer-Guittaut, Michaël, additional, and Hervouet, Eric, additional

Published
2018
Full Text
View/download PDF

45. First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report

Author

Meynard, Guillaume, primary, Mansi, Laura, additional, Lebahar, Pierre, additional, Villanueva, Cristian, additional, Klajer, Elodie, additional, Calcagno, Fabien, additional, Vivalta, Adrian, additional, Chaix, Marie, additional, Collonge-Rame, Marie-Agnès, additional, Populaire, Céline, additional, Algros, Marie-Paule, additional, Colpart, Prudence, additional, Neidich, Julie, additional, Pivot, Xavier, additional, and Curtit, Elsa, additional

Published
2017
Full Text
View/download PDF

46. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one : National Harbor, MD, USA. 9-13 November 2016

Author

Lundqvist, Andreas, Lundqvist, Andreas, van Hoef, Vincent, Zhang, Xiaonan, Wennerberg, Erik, Lorent, Julie, Witt, Kristina, Sanz, Laia Masvidal, Liang, Shuo, Murray, Shannon, Larsson, Ola, Kiessling, Rolf, Mao, Yumeng, Sidhom, John-William, Bessell, Catherine A, Havel, Jonathan, Schneck, Jonathan, Chan, Timothy A, Sachsenmeier, Eliot, Woods, David, Berglund, Anders, Ramakrishnan, Rupal, Sodre, Andressa, Weber, Jeffrey, Zappasodi, Roberta, Li, Yanyun, Qi, Jingjing, Wong, Philip, Sirard, Cynthia, Postow, Michael, Newman, Walter, Koon, Henry, Velcheti, Vamsidhar, Callahan, Margaret K, Wolchok, Jedd D, Merghoub, Taha, Lum, Lawrence G, Choi, Minsig, Thakur, Archana, Deol, Abhinav, Dyson, Gregory, Shields, Anthony, Haymaker, Cara, Uemura, Marc, Murthy, Ravi, James, Marihella, Wang, Daqing, Brevard, Julie, Monaghan, Catherine, Swann, Suzanne, Geib, James, Cornfeld, Mark, Chunduru, Srinivas, Agrawal, Sudhir, Yee, Cassian, Wargo, Jennifer, Patel, Sapna P, Amaria, Rodabe, Tawbi, Hussein, Glitza, Isabella, Woodman, Scott, Hwu, Wen-Jen, Davies, Michael A, Hwu, Patrick, Overwijk, Willem W, Bernatchez, Chantale, Diab, Adi, Massarelli, Erminia, Segal, Neil H, Ribrag, Vincent, Melero, Ignacio, Gangadhar, Tara C, Urba, Walter, Schadendorf, Dirk, Ferris, Robert L, Houot, Roch, Morschhauser, Franck, Logan, Theodore, Luke, Jason J, Sharfman, William, Barlesi, Fabrice, Ott, Patrick A, Mansi, Laura, Kummar, Shivaani, Salles, Gilles, Carpio, Cecilia, Meier, Roland, Krishnan, Suba, McDonald, Dan, Maurer, Matthew, Gu, Xuemin, Neely, Jaclyn, Suryawanshi, Satyendra, Levy, Ronald, Khushalani, Nikhil, Wu, Jennifer, Zhang, Jinyu, Basher, Fahmin, Rubinstein, Mark, Bucsek, Mark, Qiao, Guanxi, Lundqvist, Andreas, Lundqvist, Andreas, van Hoef, Vincent, Zhang, Xiaonan, Wennerberg, Erik, Lorent, Julie, Witt, Kristina, Sanz, Laia Masvidal, Liang, Shuo, Murray, Shannon, Larsson, Ola, Kiessling, Rolf, Mao, Yumeng, Sidhom, John-William, Bessell, Catherine A, Havel, Jonathan, Schneck, Jonathan, Chan, Timothy A, Sachsenmeier, Eliot, Woods, David, Berglund, Anders, Ramakrishnan, Rupal, Sodre, Andressa, Weber, Jeffrey, Zappasodi, Roberta, Li, Yanyun, Qi, Jingjing, Wong, Philip, Sirard, Cynthia, Postow, Michael, Newman, Walter, Koon, Henry, Velcheti, Vamsidhar, Callahan, Margaret K, Wolchok, Jedd D, Merghoub, Taha, Lum, Lawrence G, Choi, Minsig, Thakur, Archana, Deol, Abhinav, Dyson, Gregory, Shields, Anthony, Haymaker, Cara, Uemura, Marc, Murthy, Ravi, James, Marihella, Wang, Daqing, Brevard, Julie, Monaghan, Catherine, Swann, Suzanne, Geib, James, Cornfeld, Mark, Chunduru, Srinivas, Agrawal, Sudhir, Yee, Cassian, Wargo, Jennifer, Patel, Sapna P, Amaria, Rodabe, Tawbi, Hussein, Glitza, Isabella, Woodman, Scott, Hwu, Wen-Jen, Davies, Michael A, Hwu, Patrick, Overwijk, Willem W, Bernatchez, Chantale, Diab, Adi, Massarelli, Erminia, Segal, Neil H, Ribrag, Vincent, Melero, Ignacio, Gangadhar, Tara C, Urba, Walter, Schadendorf, Dirk, Ferris, Robert L, Houot, Roch, Morschhauser, Franck, Logan, Theodore, Luke, Jason J, Sharfman, William, Barlesi, Fabrice, Ott, Patrick A, Mansi, Laura, Kummar, Shivaani, Salles, Gilles, Carpio, Cecilia, Meier, Roland, Krishnan, Suba, McDonald, Dan, Maurer, Matthew, Gu, Xuemin, Neely, Jaclyn, Suryawanshi, Satyendra, Levy, Ronald, Khushalani, Nikhil, Wu, Jennifer, Zhang, Jinyu, Basher, Fahmin, Rubinstein, Mark, Bucsek, Mark, and Qiao, Guanxi

Published
2016

47. Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells

Author

Galaine, Jeanne, primary, Kellermann, Guillaume, additional, Guillaume, Yves, additional, Boidot, Romain, additional, Picard, Emilie, additional, Loyon, Romain, additional, Queiroz, Lise, additional, Boullerot, Laura, additional, Beziaud, Laurent, additional, Jary, Marine, additional, Mansi, Laura, additional, André, Claire, additional, Lethier, Lydie, additional, Ségal-Bendirdjian, Evelyne, additional, Borg, Christophe, additional, Godet, Yann, additional, and Adotévi, Olivier, additional

Published
2016
Full Text
View/download PDF

48. Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Author

Beziaud, Laurent, primary, Mansi, Laura, additional, Ravel, Patrice, additional, Marie-Joseph, Elodie Lauret, additional, Laheurte, Caroline, additional, Rangan, Laurie, additional, Bonnefoy, Francis, additional, Pallandre, Jean-René, additional, Boullerot, Laura, additional, Gamonet, Clémentine, additional, Vrecko, Sindy, additional, Queiroz, Lise, additional, Maurina, Tristan, additional, Mouillet, Guillaume, additional, Hon, Thierry Nguyen Tan, additional, Curtit, Elsa, additional, Royer, Bernard, additional, Gaugler, Béatrice, additional, Bayry, Jagadeesh, additional, Tartour, Eric, additional, Thiery-Vuillemin, Antoine, additional, Pivot, Xavier, additional, Borg, Christophe, additional, Godet, Yann, additional, and Adotévi, Olivier, additional

Published
2016
Full Text
View/download PDF

50. Modulation of antitumor T cell responses induced by everolimus in metastatic Renal Cell Carcinoma patients.

Author

Adotevi, Olivier, primary, Beziaud, Laurent, additional, Mansi, Laura, additional, Laheurte, Caroline, additional, Nguyen, Thierry, additional, Maurina, Tristan, additional, Mouillet, Guillaume, additional, Queiroz, Lise, additional, Jacquemard, Claire, additional, Godet, Yann, additional, Royer, Bernard, additional, Thiery-Vuillemin, Antoine, additional, and Borg, Christophe, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results